DCM
BIIB icon

Davis Capital Management’s Biogen BIIB Stock Holding History

Davis Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864 Buy
4
+2
+100% +$383 ﹤0.01% 512
2026
Q1 		$367 Hold
2
– – ﹤0.01% 463
2025
Q4 		$352 Hold
2
– – ﹤0.01% 469
2025
Q3 		$280 Buy
+2
New +$270 ﹤0.01% 502

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Davis Capital Management's BIIB Position: Q2 2026 in Review

Davis Capital Management increased its Biogen (BIIB) stake by 100% in Q2 2026, buying an estimated $383 and bringing the position to 4 shares worth $864. The position accounts for ﹤0.01% of the portfolio, ranked #512.

Davis Capital Management first reported a position in BIIB in Q3 2025 and has held it in 4 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Davis Capital Management held 4 shares of Biogen worth $864 as of Q2 2026.
  • Davis Capital Management bought 2 Biogen shares in Q2 2026, an estimated $383.
  • Biogen made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #512 holding.
  • Davis Capital Management first reported a position in Biogen in Q3 2025 and has held it in 4 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.